Ar­genx drops post-Covid syn­drome pro­gram; Mirum picks a dose for bile duct dis­ease drug

Plus, news about Y-Bi­o­log­ics, Nav­i­ga­tor Med­i­cines, Spur Ther­a­peu­tics, Disc Med­i­cine and Mereo Bio­Phar­ma:

Ar­genx ax­es Covid-dri­ven POTS pro­gram: The Dutch biotech’s ef­gar­tigi­mod did not …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.